What is the recommended treatment for atypical lobular hyperplasia in situ with sclerosing adenosis?

Treatment for Atypical Lobular Hyperplasia with Sclerosing Adenosis

For atypical lobular hyperplasia (ALH) diagnosed on core needle biopsy with concurrent sclerosing adenosis, active surveillance without surgical excision is safe and appropriate when imaging and pathology are concordant, though risk-reduction endocrine therapy should be discussed for postmenopausal women. 1, 2

Initial Management Decision

Surgical Excision vs. Active Surveillance

Active surveillance is the preferred approach for pure ALH, even when accompanied by sclerosing adenosis, provided there is radiologic-pathologic concordance. 2, 3

• Recent high-quality evidence demonstrates that pure ALH managed conservatively has a 3-year failure rate of only 6.2%, with no cases of ipsilateral same-quadrant breast cancer development during follow-up 2
• The upgrade rate to malignancy for ALH is extremely low at 2.1%, with all lesions managed by active surveillance remaining stable (50%), resolving (47%), or decreasing in size (3%) over a median 22.5-month follow-up 4
• Surgical excision should be reserved for radiologically discordant lesions or those showing progression on surveillance imaging 2, 3

Critical Caveat: Sclerosing Adenosis Recognition

The presence of sclerosing adenosis requires careful attention because it can mask coexistent invasive carcinoma and may be associated with radial sclerosing lesions that warrant excision. 5, 6

• When sclerosing adenosis is a major component (≥50%) at core biopsy, coexistent malignancy was found in 4 of 44 cases (9%) in one series, all presenting as clustered calcifications 5
• Radial sclerosing lesions associated with sclerosing adenosis are prospectively recognized in only 50% of cases and should prompt surgical excision when identified 5
• If the imaging shows spiculated masses or the pathology report mentions radial sclerosing lesions, proceed to surgical excision 5

Surveillance Protocol for Conservative Management

For ALH with sclerosing adenosis managed without surgery, implement 6-month interval imaging for at least 2 years. 4, 2

• The 3-year risk of requiring subsequent core needle biopsy is 9.2% 2
• Any progressive imaging abnormalities at the initial biopsy site warrant excisional biopsy 2
• Acceptable imaging findings for conservative management include circumscribed masses, indistinctly marginated nonpalpable masses, and clustered amorphous, pleomorphic, or punctate calcifications 5

Risk-Reduction Endocrine Therapy

All postmenopausal women with ALH should be offered endocrine therapy for breast cancer risk reduction, as ALH confers significantly elevated breast cancer risk. 1

Postmenopausal Women - Treatment Options:

Anastrozole 1 mg daily for 5 years is a first-line option (strong recommendation, high-quality evidence) 1:

• Women with atypical lobular hyperplasia are specifically identified as most likely to benefit 1
• Before initiating anastrozole, evaluate baseline fracture risk and measure bone mineral density 1
• Use with caution in women with moderate bone loss; consider bisphosphonates or RANKL inhibitors 1
• Severe osteoporosis (T-score <-4 or >2 vertebral fractures) is a relative contraindication 1
• Counsel patients about joint stiffness, arthralgias, vasomotor symptoms, hypertension, dry eyes, and vaginal dryness 1

Alternative agents for postmenopausal women include:

• Exemestane 25 mg daily for 5 years (moderate recommendation) 1
• Tamoxifen 20 mg daily for 5 years (strong recommendation) 1
• Raloxifene 60 mg daily for 5 years, particularly beneficial in women with osteoporosis where breast cancer risk reduction is a secondary benefit 1

Premenopausal Women:

Tamoxifen is the only appropriate endocrine therapy option for premenopausal women with ALH 1:

• Aromatase inhibitors (anastrozole, exemestane) and raloxifene should NOT be prescribed for breast cancer risk reduction in premenopausal women 1
• Tamoxifen should not be used in women with history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prolonged immobilization 1

Key Clinical Pitfalls to Avoid

• Do not assume all sclerosing adenosis is benign - it can harbor occult invasive carcinoma that may present with lymph node metastasis 6
• Do not miss radial sclerosing lesions on pathology reports, as these warrant excision even when ALH alone would not 5
• Do not offer aromatase inhibitors to premenopausal women - this is explicitly contraindicated 1
• Do not skip bone density assessment before starting aromatase inhibitors in postmenopausal women 1